Faculty Opinions recommendation of Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.

Author(s):  
John Furness
2009 ◽  
Vol 137 (4) ◽  
pp. 1425-1434 ◽  
Author(s):  
Sabine Buhner ◽  
Qin Li ◽  
Sheila Vignali ◽  
Giovanni Barbara ◽  
Roberto De Giorgio ◽  
...  

2011 ◽  
Vol 140 (5) ◽  
pp. S-521 ◽  
Author(s):  
Sabine Buhner ◽  
Qin Li ◽  
Breg Braak ◽  
Tamira K. Klooker ◽  
Sheila Vignali ◽  
...  

2016 ◽  
Vol 22 (2) ◽  
pp. 310-320 ◽  
Author(s):  
Shan Li ◽  
Guijun Fei ◽  
Xiucai Fang ◽  
Xilin Yang ◽  
Xiaohong Sun ◽  
...  

2007 ◽  
Vol 132 (1) ◽  
pp. 17-25 ◽  
Author(s):  
Michael Camilleri ◽  
Christopher N. Andrews ◽  
Adil E. Bharucha ◽  
Paula J. Carlson ◽  
Irene Ferber ◽  
...  

2020 ◽  
Author(s):  
Ferdinando Bonfiglio ◽  
Xingrong Liu ◽  
Christopher Smillie ◽  
Anita Pandit ◽  
Alexander Kurilshikov ◽  
...  

ABSTRACTObjectiveGut dysmotility is associated with constipation, diarrhea, and functional gastrointestinal disorders (FGID) like irritable bowel syndrome (IBS). Its molecular underpinnings, and their anomalies in FGID disorders are poorly characterized, hence we sought to gain mechanistic insight through a large-scale genetic investigation.DesignWe used stool frequency (STL-FRQ) as a (surrogate) quantitative trait to study the genetics of gut motility, exploiting questionnaire and genotype data from UK Biobank and four smaller population-based cohorts (LifeLines-Deep, Genes for Good, Flemish Gut Flora Project and PopCol), in a GWAS meta-analysis spanning 8,817,117 high-quality SNP markers and 167,875 individuals of European descent.ResultsWe identify 13 genome-wide significant loci (P≤5.0×10−8) harboring prioritized genes that are: i) involved in sensory perception and neurotransmitter/neuropeptide signaling; ii) enriched for their expression in enteric motor neurons associated with the control of peristalsis (P=7.0×10−8) iii) previously linked to other traits and conditions, including GI motility and dysmotility syndromes, and the response to their pharmacological treatment. The genetic architecture of STL-FRQ most strongly correlates with that of IBS (rg=0.42; P=1.1×10−3). In UK Biobank, the risk of IBS with diarrhea was 4x higher in individuals from the top 1% of the distribution of polygenic scores (PGS) computed based on STL-FRQ GWAS summary statistics (ORs=4.14; P=1.2×10−97).ConclusionWe identify loci harboring genes with a plausible role in GI motility, possibly acting via neurotransmission and similar pathways in specialized enteric neurons. The demonstrated relevance of these findings to IBS warrants further study for the identification of actionable pathomechanisms in the dysmotility syndromes.


2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S487-S488
Author(s):  
O Sezgin ◽  
B Boztepe ◽  
E Altintas ◽  
D Çelikcan

Abstract Background The objective of the study is to establish the frequency of irritable bowel syndrome (IBS) in patients with inflammatory bowel disease in clinical and deep remission and correlation with inflammation markers. Methods In this study, patients with ulcerative colitis (UC), and with Crohn disease (CD) in clinical remission for at least 6 months enrolled. All of the patients underwent colonoscopy and biopsy specimens were taken to evaluate endoscopic and histopathologic remission. All of the cases were given a questionnaire using the Rome III criteria for IBS and faecal specimens for calprotectin analysis, and blood samples for CRP, sedimentation rate and fibrinogen levels were taken. Results IBS frequency was 20.9% in UC cases in clinical remission, 28.9% in CD cases, and did not vary by the presence or absence of endoscopic remission (20,5% vs.22,2% in UC, p:0,727, 25% vs.33,3% in CD, p:0,837) or histopathologic remission (15,7% vs.26,6% in UC, p:0,723, 21,4% vs.33,3% in CD respectively, p:0,999). The incidence of IBS did not change statistically with deepening of remission in both diseases. It was not related to inflammation markers Conclusion IBS frequency among IBD patients in clinical remission was 21–29% and did not vary by the presence or absence of endoscopic or histopathologic remission or by inflammation markers levels. This suggests that IBS may not be related to ongoing subclinical inflammation in IBD in remission.


2001 ◽  
Vol 120 (5) ◽  
pp. A399-A399
Author(s):  
J STEENS ◽  
P SCHAAR ◽  
C LAMERS ◽  
A MASCLEE

Sign in / Sign up

Export Citation Format

Share Document